Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New studies back success of PTMR (percutaneous transmyocardial revascularisation) for heart patients although researchers still unable to explain mechanism

This article was originally published in Clinica

Executive Summary

Two studies have had added further evidence to back the clinical benefits of percutaneous transmyocardial revascularisation (PTMR) as a potential treatment for patients with severe angina who cannot undergo angioplasty or bypass surgery.

You may also be interested in...



Perrigo Launches OTC Viagra Rival In UK

Perrigo is launching in the UK an OTC sildenafil generic to compete with Pfizer's erectile dysfunction drug Viagra Connect.

New Filings At The EMA

New medicines under evaluation at the European Medicines Agency.

Pfizer Warns Doctors About Blood Clot Risk With Xeljanz

Now that the European Medicines Agency has finalized its formal safety review procedure into Xeljanz, Pfizer is telling health care professionals what precautions they must take when prescribing the drug.

Topics

UsernamePublicRestriction

Register

MT075689

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel